Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H ( (HK:2185) ) has provided an announcement.
Shanghai Bio-heart Biological Technology Co., Ltd. has announced the successful registration of its Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System in New Zealand. This system is notable for being the only renal denervation product approved globally with both transradial and transfemoral approaches, aiming to make renal denervation procedures safer, more effective, and cost-efficient, with the ultimate goal of facilitating outpatient procedures worldwide.
More about Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
Shanghai Bio-heart Biological Technology Co., Ltd. is a company based in the People’s Republic of China, operating in the medical technology industry. It focuses on developing innovative medical devices, particularly in the field of renal denervation, through its subsidiary Shanghai AngioCare Medical Technology Co., Ltd.
Average Trading Volume: 1,691,031
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.51B
For an in-depth examination of 2185 stock, go to TipRanks’ Overview page.